0,05. Доказательная медицина от магии до поисков бессмертия

Podolanczuk A. J., Lederer D. J. Patient-centered outcomes in idiopathic pulmonary fibrosis clinical trials // American Journal of Respiratory and Critical Care Medicine. 2017. September 15. Vol. 196. № 6. P. 674–675.

Lassere M. N., Johnson K. R., Boers M., Tugwell P., Brooks P., Simon L., Strand V. et al. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema // The Journal of rheumatology. 2007. March. Vol. 34. № 3. P. 607–615.

Hunter D. J., Losina E., Guermazi A., Burstein D., Lassere M. N., Kraus V. A pathway and approach to biomarker validation and qualification for osteoarthritis clinical trials // Current drug targets. 2010. May. Vol. 11. № 5. P. 536–545.

Chan A.-W., Hróbjartsson A., Haahr M. T. et al. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles // JAMA. 2004. May 26. Vol. 291. № 20. P. 2457–2465.

Lee K. L., McNeer J. F., Starmer C. F., Harris P. J., Rosati R. A. Clinical judgment and statistics. Lessons from a simulated randomized trial in coronary artery disease // Circulation. 1980. March. Vol. 61. № 3. P. 508–515.

Rothwell P. M. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation // Lancet. 2005. January. Vol. 365. P. 176–186.

Stallones R. A. The use and abuse of subgroup analysis in epidemiological research // Preventive medicine. 1987. March. Vol. 16. № 2. P. 183–194.

Oxman A. D., Guyatt G. H. A Consumer’s guide to subgroup analyses // Annals of internal medicine. 1992. January. Vol. 116. № 1. P. 78–84.

Sterne J. A. C., Smith G. D. Sifting the evidence – what’s wrong with significance tests? // Physical Therapy. 2001. August 1. Vol. 81. № 8. P. 1464–1469.

Guyatt G., Jaeschke R., Heddle N., Cook D., Shannon H., Walter S. Basic statistics for clinicians: 2. Interpreting study results: confidence intervals // Canadian Medical Association journal. 1995. January. Vol. 152. № 2. P. 169–173.

Kääriäinen I., Sipponen P., Siurala M. What fraction of hospital ulcer patients is eligible for prospective drug trials? // Scandinavian journal of gastroenterology. 1991. Vol. 26. № 186. P. 73–76.

Charlson M. E., Horwitz R. I. Applying results of randomised trials to clinical practice: impact of losses before randomisation // British medical journal. 1984. November 10. Vol. 289. P. 1281–1284.

Simpson S. H., Eurich D. T., Majumdar S. R., Padwal R. S., Tsuyuki R. T. et al. A meta-analysis of the association between adherence to drug therapy and mortality // BMJ. 2006. July 1. Vol. 333. № 7557.

Mitchell J. “But will it help my patients with myocardial infarction?” The implications of recent trials for everyday country folk // British Medical Journal. 1982. October 23. Vol. 285. P. 1140–1148.

Shepherd J. Statins for primary prevention: strategic options to save lives and money // Journal of the Royal Society of Medicine. 2004. February. Vol. 97. № 2. P. 66–71.

Asymptomatic Carotid Atherosclerosis Study Group. Carotid endarterectomy for patients with asymptomatic internal carotid artery stenosis // JAMA. 1995. Vol. 273. P. 1421–1428.

Moore W. S., Young B., Baker W. H. et al. Surgical results: a justification of the surgeon selection process for the ACAS trial // Journal of Vascular Surgery. 1996. Vol. 23. P. 323–328.